| AR | LNCaP (prostate carcinoma) | Vehicle | Permissive | Homo sapiens | GSE28126
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | AR stimulated | Permissive
      
      Robust | Homo sapiens | GSE28126
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | Vehicle | Permissive
      
      Robust | Homo sapiens | GSE28126
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | AR stimulated | Permissive
      
      Robust | Homo sapiens | GSE28126
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | NT | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | siERG | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 10nm R | Permissive | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1nm R | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | ethanol | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | ethanol | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Vehicle | Permissive | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1000 nM Bica | Permissive | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 100 nM DHT | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 100 nM DHT+Dex | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1000 nM CPA | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1000 nM RU486 | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | 100 nM DHT | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT for 4h | Permissive
      
      Robust | Homo sapiens | GSE32345
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCS2 (prostate carcinoma) | DHT for 4h | Permissive
      
      Robust | Homo sapiens | GSE32345
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | kidney | castrated+vehicle | Permissive | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | castrated+vehicle | Permissive
      
      Robust | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate | castrated+vehicle | Permissive | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate | castrated+testosterone | Permissive
      
      Robust | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | kidney | castrated+testosterone | Permissive
      
      Robust | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | intact | Permissive
      
      Robust | Mus musculus | GSE47192
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | specificity affecting androgen receptor knock-in | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | specificity affecting androgen receptor knock-in | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | ventral prostate | specificity affecting androgen receptor knock-in | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | BICALUTAMIDE | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Vehicle | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | BICALUTAMIDE | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | BICALUTAMIDE | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Vehicle | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | BICALUTAMIDE | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Vehicle | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Vehicle | Permissive
      
      Robust | Homo sapiens | GSE49832
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEK293 (embryonic kidney) | Ethanol | Permissive | Homo sapiens | GSE54109
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEK293 (embryonic kidney) | 10 nM R1881 | Permissive
      
      Robust | Homo sapiens | GSE54109
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEK293 (embryonic kidney) | 10 nM R1881 | Permissive
      
      Robust | Homo sapiens | GSE54109
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Bicalutamide | Permissive
      
      Robust | Homo sapiens | GSE51063
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Enzalutamide | Permissive | Homo sapiens | GSE51063
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP C4-2 (prostate carcinoma) | ethanol | Permissive | Homo sapiens | GSE55031
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP C4-2 (prostate carcinoma) | 10 nmol/l of mibolerone | Permissive
      
      Robust | Homo sapiens | GSE55031
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | ethanol | Permissive
      
      Robust | Homo sapiens | GSE55031
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 10 nmol/l of mibolerone | Permissive
      
      Robust | Homo sapiens | GSE55031
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | ovarian granulosa cells | Insertion | Permissive | Homo sapiens | GSE58628
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | ovarian granulosa cells | Deletion | Permissive | Homo sapiens | GSE58628
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | CWR22 (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE62442
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | CWR22 (prostate carcinoma) | DHT+Bicalutamide | Permissive
      
      Robust | Homo sapiens | GSE62442
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | CWR22 (prostate carcinoma) | DHT+MDV3100 | Permissive
      
      Robust | Homo sapiens | GSE62442
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate tumor | castrate | Permissive | Mus musculus | GSE62645
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate tumor | bicalutamide | Permissive
      
      Robust | Mus musculus | GSE62645
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate tumor | enzalutamide | Permissive | Mus musculus | GSE62645
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP C4-2 (prostate carcinoma) | ethanol | Permissive | Homo sapiens | GSE65066
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP C4-2 (prostate carcinoma) | 10 nmol/l of mibolerone | Permissive
      
      Robust | Homo sapiens | GSE65066
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | ethanol | Permissive
      
      Robust | Homo sapiens | GSE65066
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 10 nmol/l of mibolerone | Permissive
      
      Robust | Homo sapiens | GSE65066
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Bicalutamide 1 μM | Permissive | Homo sapiens | GSE66037
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | BicR (prostate cancer) | DHT 10 nM | Permissive
      
      Robust | Homo sapiens | GSE66037
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | BicR (prostate cancer) | Bicalutamide 1 μM | Permissive | Homo sapiens | GSE66037
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | BicR (prostate cancer) | ethanol | Permissive | Homo sapiens | GSE66037
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | siControl | Permissive
      
      Robust | Homo sapiens | GSE77770
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | siOCT1 | Permissive
      
      Robust | Homo sapiens | GSE77770
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | siControl | Permissive
      
      Robust | Homo sapiens | GSE77770
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | siOCT1 | Permissive
      
      Robust | Homo sapiens | GSE77770
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 72 hour CDT + 3 hour EtOH | Permissive | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | treated for 24 hours with 0.5μM PD-0332991 +3 hour 10nm DHT | Permissive
      
      Robust | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | treated for 24 hours with 5μg/mL roscovitine + 3 hour DHT | Permissive | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | treated for 24 hours with 2μg/mL aphidicolin +3 hour 10nm DHT | Permissive
      
      Robust | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | treated for 24 hours with 1mM hydroxyurea +3 hour 10nm DHT | Permissive
      
      Robust | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 2μg/mL aphidicolin for 15 hours, followed by washout and treatment with 50ng/mL nocodozole for 9 hours +3 hour 10nm DHT | Permissive
      
      Robust | Homo sapiens | GSE82202
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-D567 (prostate cancer) | radiation | Permissive
      
      Robust | Homo sapiens | GSE102164
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE73994
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881+Doxycycline | Permissive
      
      Robust | Homo sapiens | GSE73994
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | NOV induced | Permissive
      
      Robust | Homo sapiens | GSE79357
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | dihydrotestosterone  (DHT) | Permissive
      
      Robust | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | Control | Permissive | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | dihydrotestosterone  (DHT) | Permissive
      
      Robust | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Control | Permissive
      
      Robust | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | dihydrotestosterone (DHT) | Permissive
      
      Robust | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Control | Permissive | Homo sapiens | GSE92347
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | breast tumor | Female | Permissive
      
      Robust | Homo sapiens | GSE104399
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | MCF-7 C4-12 (invasive breast ductal carcinoma) | Female | Permissive
      
      Robust | Homo sapiens | GSE104399
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation ,  ethanol,  knockout control Genotype: wildtype Source: prostate cancer cells | Permissive
      
      Robust | Homo sapiens | GSE108144
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol, shTRIM24 Genotype: wildtype Source: prostate cancer cells | Permissive
      
      Robust | Homo sapiens | GSE108144
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: CaP cells were infected with EZH2 knockdown lentivirus and maintained for 2-3 days before fixation, ethanol , shTRIM28 Genotype: wildtype Source: prostate cancer cells | Permissive | Homo sapiens | GSE108144
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEE (human epididymis epithelial cells) | Treatment: without treatment of R1881 (methyltrienolone) | Permissive | Homo sapiens | GSE109061
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEE (human epididymis epithelial cells) | Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr | Permissive
      
      Robust | Homo sapiens | GSE109061
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEE (human epididymis epithelial cells) | Treatment: without treatment of R1881 (methyltrienolone) | Permissive | Homo sapiens | GSE109061
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HEE (human epididymis epithelial cells) | Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr | Permissive
      
      Robust | Homo sapiens | GSE109061
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | A375 (malignant melanoma) | Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) empty vector control for 24 hr, post-seeding using Lipofectamine 2000 | Permissive | Homo sapiens | GSE116189
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | A375 (malignant melanoma) | Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) vector expressing SLNCR1 for 24 hr, post-seeding using Lipofectamine 2000 | Permissive | Homo sapiens | GSE116189
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP-abl (Prostate carcinoma) | Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive | Permissive
      
      Robust | Homo sapiens | GSE80238
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP-abl (Prostate carcinoma) | Treatment: EPZ-6438 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive | Permissive | Homo sapiens | GSE80238
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP-abl (Prostate carcinoma) | Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive | Permissive
      
      Robust | Homo sapiens | GSE80238
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: non-target siNT+R1881 | Permissive
      
      Robust | Homo sapiens | GSE80742
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | treatment: targeting ARV1/3/4/7 siARVs+R1881 | Permissive
      
      Robust | Homo sapiens | GSE80742
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: targeting AR exon 7 siARFL+ ethanol | Permissive
      
      Robust | Homo sapiens | GSE80742
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Cells were harvested in log phase growth Genotype: wildtype | Permissive
      
      Robust | Homo sapiens | GSE85558
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Cells were harvested in log phase growth Genotype: HNF4G overexpression | Permissive
      
      Robust | Homo sapiens | GSE85558
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: Cells were harvested in log phase growth Genotype: wildtype | Permissive
      
      Robust | Homo sapiens | GSE85558
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: Cells were harvested in log phase growth Genotype: knockdown HNF4G | Permissive | Homo sapiens | GSE85558
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | hNSC (neural stem cells) | Treatment: DMSO 4 hours | Permissive | Homo sapiens | GSE86454
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | hNSC (neural stem cells) | Treatment: DHT 10nM 4 hours | Permissive | Homo sapiens | GSE86454
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | hNSC (neural stem cells) | Treatment: Testosterone 100nM 4 hours | Permissive | Homo sapiens | GSE86454
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: DMSO 4 hours | Permissive | Homo sapiens | GSE86456
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: DMSO 4 hours | Permissive | Homo sapiens | GSE86456
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: DHT 100nM 4 hours | Permissive | Homo sapiens | GSE86456
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: DHT 100nM 4 hours | Permissive
      
      Robust | Homo sapiens | GSE86456
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: control | Permissive
      
      Robust | Homo sapiens | GSE120738
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: exclude | Permissive
      
      Robust | Homo sapiens | GSE120738
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: case | Permissive
      
      Robust | Homo sapiens | GSE120738
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout | Permissive | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and vector | Permissive | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and vector | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout and Bag-1L wildtype | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs  Genotype: Bag-1L wildtype | Permissive | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L wildtype | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: Ethanol for 4 hrs | Permissive | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nM DHT for 4 hrs Genotype: Bag-1L knockout | Permissive
      
      Robust | Homo sapiens | GSE89938
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: vehicle (charcoal stripped) for 6 hrs  TF: full-length AR (AR-FL) | Permissive
      
      Robust | Homo sapiens | GSE94013
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: 10 nM DHT for 6 hrs TF: full-length AR (AR-FL) | Permissive
      
      Robust | Homo sapiens | GSE94013
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: 10 nM DHT+ 500 nM JQ1 for 6 hrs  TF: full-length AR (AR-FL) | Permissive
      
      Robust | Homo sapiens | GSE94013
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | Treatment: 10 nM DHT+10 uM MDV3100 TF: full-length AR (AR-FL) | Permissive
      
      Robust | Homo sapiens | GSE94013
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HIV-1 latently-infected central memory T cells cultured from uninfected primary T cells | Treatment: 24h ethanol | Permissive | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 24h DHT 1 nM | Permissive | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LTAD (long term androgen deprivation) | Treatment: 24h DHT 1 nM | Permissive | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP and LTAD cells | Treatment: 24h DHT 10 nM | Permissive
      
      Robust | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP and LTAD cells | Treatment: 24h DHT 1 nM | Permissive
      
      Robust | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LTAD (long term androgen deprivation) | Treatment: 24h DHT 10 nM siControl treated | Permissive
      
      Robust | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LTAD (long term androgen deprivation) | Treatment: 24h DHT 10 nM siCOBLL1 treated | Permissive | Homo sapiens | GSE94577
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: treated with 10nM  vehicle for 4 hours | Permissive | Homo sapiens | GSE94682
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: treated with 10nM  R1881 for 4 hours | Permissive
      
      Robust | Homo sapiens | GSE94682
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-AD1 (prostate cancer) | Treatment: 0.1% DMSO + 1 nM ethanol for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE96084
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-AD1 (prostate cancer) | Treatment: 0.1% DMSO + 1 nM DHT for 4 hrs | Permissive | Homo sapiens | GSE96084
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-AD1 (prostate cancer) | Treatment: 50 uM VPC14449 + 1 nM ethanol for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE96084
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-D567 (prostate cancer) | Treatment: 0.1% DMSO for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE96084
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-D567 (prostate cancer) | Treatment: 50 uM VPC14449 for 4 hrs | Permissive
      
      Robust | Homo sapiens | GSE96084
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10 nM ETOH for 4 hrs Genotype: shARfl transfection | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10 nM ETOH for 4 hrs Genotype: shGFP transfection | Permissive | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10nM DHT for 4 hrs Genotype: shGFP | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10 nM ETOH for 4 hrs Genotype: shARv7 transfection | Permissive | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection) | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10 nM ETOH for 4 hrs Genotype: parental (none transfection) | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP95 | Treatment: 10nM DHT for 4 hrs Genotype: shARv7 transfection | Permissive
      
      Robust | Homo sapiens | GSE106559
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of DHT for 2 hrs | Permissive
      
      Robust | Homo sapiens | GSE108704
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment:  transfected twice with with 5nM of siControl every 24 hours, 100nM of ETOH for 2 hrs, 100nM of ETOH for 2 hrs | Permissive
      
      Robust | Homo sapiens | GSE108704
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment:  transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of DHT for 2 hrs Genotype: transfected with siLINC00844 | Permissive
      
      Robust | Homo sapiens | GSE108704
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment:  transfected twice with with 5nM of siLINC00844 every 24 hours, 100nM of ETOH for 2 hrs Genotype: transfected with siLINC00844 | Permissive | Homo sapiens | GSE108704
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: FA (control) | Permissive
      
      Robust | Homo sapiens | GSE114737
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment:  2 mM DSG for 25 mins | Permissive
      
      Robust | Homo sapiens | GSE114737
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | primary prostate cancer | Treatment: FA (control) | Permissive
      
      Robust | Homo sapiens | GSE114737
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | primary prostate cancer | Treatment:  2 mM DSG for 25 mins | Permissive
      
      Robust | Homo sapiens | GSE114737
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | primary prostate cancer | Treatment:  2 mM DSG for 25 mins | Permissive
      
      Robust | Homo sapiens | GSE114737
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | Age: 3 months Strain: C57Bl/6N; 129 hybrid Genotype: wildtype Tissue: Caput epididymis (containing initial segment) | Permissive
      
      Robust | Mus musculus | GSE121151
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis | Age: 3 months Strain: C57Bl/6N; 129 hybrid Genotype: ArKI Tissue: Caput epididymis (containing initial segment) | Permissive
      
      Robust | Mus musculus | GSE121151
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: vehicle, control; | Permissive | Homo sapiens | GSE43720
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Treatment: 10 nm DHT; | Permissive
      
      Robust | Homo sapiens | GSE43720
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Genotype: Renilla knockout; Treatment: shRenilla; | Permissive
      
      Robust | Homo sapiens | GSE120680
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | Genotype: GREB1 knockout; Treatment: shGREB1; | Permissive
      
      Robust | Homo sapiens | GSE120680
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate cancer | Strain:: 129/C57Bl6; Treatment: CRISPR-AR; Genotype: Pten-/- Rosa26-Tmprss2-ERG, AR knockout; | Permissive | Mus musculus | GSE112414
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate cancer | Strain:129/C57Bl6; Treatment: CRISPR-ERG; Genotype: Pten-/- Rosa26-Tmprss2-ERG, ERG knockout; | Permissive
      
      Robust | Mus musculus | GSE112414
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | sperm | Strain: CD1; | Permissive | Mus musculus | GSE116855
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | SHFOXA1 | Permissive | Homo sapiens | ERP003272 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | KDP53 | Permissive
      
      Robust | Homo sapiens | GSE31294 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHCTR | Permissive
      
      Robust | Homo sapiens | GSE47120 | MA0007.3 | 
  
    
    | AR |  | FOXA1_HOXB13 | Permissive
      
      Robust | Homo sapiens | GSE56288 | MA0007.3 | 
  
    
    | AR | prostate | DHT | Permissive
      
      Robust | Homo sapiens | GSE61838 | MA0007.3 | 
  
    
    | AR | DUCaP (prostate carcinoma) | ANDROGEN | Permissive
      
      Robust | Homo sapiens | GSE70679 | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) |  | Permissive | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | metastatic prostate cancer tissue |  | Permissive
      
      Robust | Homo sapiens | GSE14092
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE39879
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Mus musculus | GSE47119
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Mus musculus | GSE47119
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Mus musculus | GSE47119
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis |  | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | caput epididymis |  | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | ventral prostate |  | Permissive
      
      Robust | Mus musculus | GSE51106
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | non-proliferating proximal caput epididymus |  | Permissive | Mus musculus | GSE38656
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | ovarian granulosa cells |  | Permissive
      
      Robust | Homo sapiens | GSE58628
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | CWR22 (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE62442
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate tumor |  | Permissive
      
      Robust | Mus musculus | GSE62645
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | R1-D567 (prostate cancer) |  | Permissive
      
      Robust | Homo sapiens | GSE102164
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE79357
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive | Homo sapiens | GSE80256
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | fetal prostate fibroblasts |  | Permissive | Homo sapiens | GSE90772
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | prostate cancer-associated fibroblasts |  | Permissive | Homo sapiens | GSE90772
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | myofibroblasts |  | Permissive | Homo sapiens | GSE90772
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE96652
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE98809
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | HDF(human dermal fibroblasts) |  | Permissive | Homo sapiens | GSE107320
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP C4-2 (prostate carcinoma) |  | Permissive | Homo sapiens | GSE97831
              
            
          
            
            ... | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | ERP001226 | MA0007.3 | 
  
    
    | AR | MCF7 (Invasive ductal breast carcinoma) |  | Permissive | Homo sapiens | ERP001226 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) |  | Permissive
      
      Robust | Homo sapiens | ERP001226 | MA0007.3 | 
  
    
    | AR | LNCaP-abl (Prostate carcinoma) |  | Permissive | Homo sapiens | GSE39459 | MA0007.3 | 
  
    
    | AR |  |  | Permissive | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE43785 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE45201 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE48308 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE48308 | MA0007.3 | 
  
    
    | AR |  |  | Permissive | Homo sapiens | GSE48308 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE48308 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE48308 | MA0007.3 | 
  
    
    | AR | MCF7 (Invasive ductal breast carcinoma) |  | Permissive | Homo sapiens | GSE48930 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE55062 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE55062 | MA0007.3 | 
  
    
    | AR |  |  | Permissive | Homo sapiens | GSE58478 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE58478 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE58478 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE63202 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE64656 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE71704 | MA0007.3 | 
  
    
    | AR |  |  | Permissive
      
      Robust | Homo sapiens | GSE71704 | MA0007.3 | 
  
    
    | AR | LNCaP C4-2B (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE72714 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | FOXA1 | Permissive
      
      Robust | Homo sapiens | ERP003503 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | FOXA1 | Permissive | Homo sapiens | ERP003503 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHAT_18H | Permissive
      
      Robust | Homo sapiens | GSE28950 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHAT_2H | Permissive
      
      Robust | Homo sapiens | GSE28950 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1F5 | Permissive
      
      Robust | Homo sapiens | GSE30623 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | 1F5_SIFOXA1 | Permissive
      
      Robust | Homo sapiens | GSE30623 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_10C26 | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_10C30 | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_1C26 | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_1C30 | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHCTR_R1881_HD | Permissive
      
      Robust | Homo sapiens | GSE37345 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHFOXA1_R1881_HD | Permissive
      
      Robust | Homo sapiens | GSE37345 | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR | LNCaP C4-2B (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE43720 | MA0007.3 | 
  
    
    | AR | DU145 (prostate carcinoma) | ARG56W | Permissive
      
      Robust | Homo sapiens | GSE47987 | MA0007.3 | 
  
    
    | AR | DU145 (prostate carcinoma) | ARQ6540X | Permissive
      
      Robust | Homo sapiens | GSE47987 | MA0007.3 | 
  
    
    | AR | DU145 (prostate carcinoma) | FOXA1_ARQ6540X | Permissive
      
      Robust | Homo sapiens | GSE47987 | MA0007.3 | 
  
    
    | AR | DU145 (prostate carcinoma) | FOXA1_HIGH | Permissive
      
      Robust | Homo sapiens | GSE47987 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHCTR | Permissive
      
      Robust | Homo sapiens | GSE52725 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHGATA2 | Permissive
      
      Robust | Homo sapiens | GSE52725 | MA0007.3 | 
  
    
    | AR | PC3(bone mets prostate adenocarcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE54110 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SHPIAS1_R1881 | Permissive
      
      Robust | Homo sapiens | GSE56086 | MA0007.3 | 
  
    
    | AR | LHSAR (prostate epithelial cells) | HOXB13 | Permissive
      
      Robust | Homo sapiens | GSE56288 | MA0007.3 | 
  
    
    | AR | LHSAR (prostate epithelial cells) | LACZ | Permissive
      
      Robust | Homo sapiens | GSE56288 | MA0007.3 | 
  
    
    | AR | prostate | cancer | Permissive
      
      Robust | Homo sapiens | GSE56288 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DHT24H | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DHT24H_SHFOXA1 | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT24H | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT24H_SHFOXA1 | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT24H_SHFOXP1 | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT24H_SHRUNX1 | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | ETOH24H | Permissive
      
      Robust | Homo sapiens | GSE58428 | MA0007.3 | 
  
    
    | AR | LNCaP C4-2B (prostate carcinoma) | ETOH_SHCTR | Permissive | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP C4-2B (prostate carcinoma) | R1881_SHCTR | Permissive
      
      Robust | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | ETOH_SHCTR | Permissive
      
      Robust | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | HOTAIR | Permissive
      
      Robust | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881_HOTAIR | Permissive
      
      Robust | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881_SHCTR | Permissive
      
      Robust | Homo sapiens | GSE61268 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE62492 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHCTR_DHT | Permissive
      
      Robust | Homo sapiens | GSE62492 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHFOXP1_DHT | Permissive
      
      Robust | Homo sapiens | GSE62492 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | ETOH | Permissive | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | R1881 | Permissive | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | RPMIFBS | Permissive
      
      Robust | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHFOXA1_PHFRPMIFCS | Permissive
      
      Robust | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHFOXA1_RPMIFBS | Permissive
      
      Robust | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHGATA2_ETOH | Permissive | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | SHGATA2_R1881 | Permissive | Homo sapiens | GSE69043 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE70161 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | R1881_SICTR | Permissive
      
      Robust | Homo sapiens | GSE70161 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | R1881_SIPIAS1 | Permissive
      
      Robust | Homo sapiens | GSE70161 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE74069 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) | MPA | Permissive
      
      Robust | Homo sapiens | GSE74069 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881 | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SH1_DHT | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SH1_R1881 | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SH2_DHT | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SH2_R1881 | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | SH3_DHT | Permissive
      
      Robust | Homo sapiens | GSE79128 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DHT | Permissive
      
      Robust | Homo sapiens | GSE83860 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DHT_TNFA | Permissive
      
      Robust | Homo sapiens | GSE83860 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) | DMSO | Permissive
      
      Robust | Homo sapiens | GSE83860 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_30M | Permissive
      
      Robust | Homo sapiens | GSE84432 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) | R1881_4H | Permissive
      
      Robust | Homo sapiens | GSE84432 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | ERP003503 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) |  | Permissive | Homo sapiens | ERP003503 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE28950 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE32892 | MA0007.3 | 
  
    
    | AR | 22RV1 (prostate carcinoma) |  | Permissive | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR | LNCaP C4-2B (prostate carcinoma) |  | Permissive | Homo sapiens | GSE40050 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive | Homo sapiens | GSE43720 | MA0007.3 | 
  
    
    | AR | DU145 (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE47987 | MA0007.3 | 
  
    
    | AR | PC3(bone mets prostate adenocarcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE54110 | MA0007.3 | 
  
    
    | AR | VCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE56086 | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Homo sapiens | GSE56288 | MA0007.3 | 
  
    
    | AR | LNCaP (prostate carcinoma) |  | Permissive
      
      Robust | Homo sapiens | GSE62492 | MA0007.3 | 
  
    
    | AR | MDA-MB-453 (breast adenocarcinoma) |  | Permissive | Homo sapiens | GSE74069 | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Homo sapiens | GSE65478 | MA0007.3 | 
  
    
    | AR | prostate |  | Permissive
      
      Robust | Homo sapiens | GSE65478 | MA0007.3 |